• Ionis Pharmaceuticals announced that it will present new one-year extension data for TRYNGOLZA and early-stage results for follow-on therapy ION775 in severe hypertriglyceridemia, alongside Phase 3 eplontersen data in transthyretin-mediated amyloid cardiomyopathy, at the ESC Congress 2026 in Munich later this month.
• This data package, spanning an approved RNA-targeted therapy, a next-generation siRNA candidate and a partnered ATTR-CM program with AstraZeneca, highlights Ionis’ broad cardiometabolic and rare disease RNA medicines platform.
• We’ll now examine how this expanded TRYNGOLZA evidence base and next-generation ION775 program shape Ionis Pharmaceuticals’ investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.

What Is Ionis Pharmaceuticals' Investment Narrative?

For Ionis, you really have to believe in the RNA medicines platform translating into a durable, multi-drug commercial business, not just one-off approvals. The upcoming ESC data on TRYNGOLZA and ION775 plug directly into that story, but are unlikely to change the near-term picture as dramatically as pivotal readouts or major regulatory decisions in Alzheimer’s, hepatitis B or Alexander disease. Where it could matter is in reinforcing TRYNGOLZA’s early launch story and showing that Ionis has a lifecycle plan via ION775, which may support confidence in revenue guidance and longer-term margin leverage if uptake builds. At the same time, the company is still loss making, reliant on partner economics and facing execution risk across a crowded late-stage pipeline, so setbacks in any of these programs would quickly reframe the current optimism.

However, investors should recognize how dependent the story is on multiple late-stage outcomes. Ionis Pharmaceuticals' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Four Simply Wall St Community fair values span roughly US$80 to a very large US$340 per share, underscoring how differently people view Ionis, especially with the latest TRYNGOLZA and ION775 update sharpening both opportunity and execution risk.

Explore 4 other fair value estimates on Ionis Pharmaceuticals - why the stock might be worth over 5x more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Ionis Pharmaceuticals research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Ionis Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ionis Pharmaceuticals' overall financial health at a glance.

Want Some Alternatives?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Find 50 companies with promising cash flow potential yet trading below their fair value.
• The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Uncover the next big thing with 21 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.